JPWO2020047327A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047327A5 JPWO2020047327A5 JP2021511583A JP2021511583A JPWO2020047327A5 JP WO2020047327 A5 JPWO2020047327 A5 JP WO2020047327A5 JP 2021511583 A JP2021511583 A JP 2021511583A JP 2021511583 A JP2021511583 A JP 2021511583A JP WO2020047327 A5 JPWO2020047327 A5 JP WO2020047327A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- amino acid
- acid sequence
- domain
- extracellular domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 79
- 102000037240 fusion proteins Human genes 0.000 claims description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 108091004535 flt3 ligand protein Proteins 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 16
- 108091005945 Type II transmembrane proteins Proteins 0.000 claims description 15
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims description 14
- 210000004027 cells Anatomy 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 8
- -1 APRIL Proteins 0.000 claims description 8
- 108010029697 CD40 Ligand Proteins 0.000 claims description 8
- 102100003729 CD40LG Human genes 0.000 claims description 8
- 108010042215 OX40 Ligand Proteins 0.000 claims description 8
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 8
- 102100009558 TNFSF18 Human genes 0.000 claims description 8
- 101710022243 TNFSF18 Proteins 0.000 claims description 8
- 102100011846 TNFSF4 Human genes 0.000 claims description 8
- 102100003084 TNFSF9 Human genes 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 230000001965 increased Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 101710006689 ITGAX Proteins 0.000 claims description 4
- 102100019437 ITGAX Human genes 0.000 claims description 4
- 210000000225 Synapses Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 102000004965 antibodies Human genes 0.000 claims description 4
- 108090001123 antibodies Proteins 0.000 claims description 4
- 230000002708 enhancing Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 230000004936 stimulating Effects 0.000 claims description 4
- 206010047461 Viral infection Diseases 0.000 claims description 3
- 208000001756 Virus Disease Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 200000000018 inflammatory disease Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 230000001603 reducing Effects 0.000 claims description 3
- 230000017613 viral reproduction Effects 0.000 claims description 3
- 102100014180 BTNL2 Human genes 0.000 claims description 2
- 101700021769 BTNL2 Proteins 0.000 claims description 2
- 102000003930 C-Type Lectins Human genes 0.000 claims description 2
- 108090000342 C-Type Lectins Proteins 0.000 claims description 2
- 101700056583 CD27 Proteins 0.000 claims description 2
- 102100019459 CD27 Human genes 0.000 claims description 2
- 102100019461 CD28 Human genes 0.000 claims description 2
- 101700033362 CD28 Proteins 0.000 claims description 2
- 101710040446 CD40 Proteins 0.000 claims description 2
- 102100013137 CD40 Human genes 0.000 claims description 2
- 102100005830 CD70 Human genes 0.000 claims description 2
- 101700017377 CD70 Proteins 0.000 claims description 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 claims description 2
- 102100019451 CD80 Human genes 0.000 claims description 2
- 101700080477 CD80 Proteins 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 102100003082 FASLG Human genes 0.000 claims description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 2
- 101700086956 IFNG Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 101710036388 KLRC1 Proteins 0.000 claims description 2
- 102100017339 KLRC1 Human genes 0.000 claims description 2
- 102100012225 KLRC2 Human genes 0.000 claims description 2
- 101710036391 KLRC2 Proteins 0.000 claims description 2
- 102100012223 KLRK1 Human genes 0.000 claims description 2
- 101710036390 KLRK1 Proteins 0.000 claims description 2
- 229940053278 LTA Drugs 0.000 claims description 2
- 210000004698 Lymphocytes Anatomy 0.000 claims description 2
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 101710040537 TNF Proteins 0.000 claims description 2
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 claims description 2
- 102100009493 TNFSF13B Human genes 0.000 claims description 2
- 101710004627 TNFSF13B Proteins 0.000 claims description 2
- 102100002239 TNFSF15 Human genes 0.000 claims description 2
- 101710022241 TNFSF15 Proteins 0.000 claims description 2
- 102100003083 TNFSF8 Human genes 0.000 claims description 2
- 101710025687 TNFSF8 Proteins 0.000 claims description 2
- 230000003213 activating Effects 0.000 claims description 2
- 230000000259 anti-tumor Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000038129 antigens Human genes 0.000 claims description 2
- 108091007172 antigens Proteins 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 230000016396 cytokine production Effects 0.000 claims description 2
- 210000003162 effector T lymphocyte Anatomy 0.000 claims description 2
- 230000002519 immonomodulatory Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000003308 immunostimulating Effects 0.000 claims description 2
- 230000001506 immunosuppresive Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002757 inflammatory Effects 0.000 claims description 2
- 230000002147 killing Effects 0.000 claims description 2
- 230000000051 modifying Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000002459 sustained Effects 0.000 claims description 2
- 210000004881 tumor cells Anatomy 0.000 claims description 2
- 102100016020 IFNG Human genes 0.000 claims 1
- 210000001165 Lymph Nodes Anatomy 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724596P | 2018-08-29 | 2018-08-29 | |
| US62/724,596 | 2018-08-29 | ||
| PCT/US2019/048922 WO2020047327A2 (en) | 2018-08-29 | 2019-08-29 | Flt3l-based chimeric proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512540A JP2022512540A (ja) | 2022-02-07 |
| JPWO2020047327A5 true JPWO2020047327A5 (de) | 2022-09-06 |
Family
ID=69643788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511583A Pending JP2022512540A (ja) | 2018-08-29 | 2019-08-29 | Ｆｌｔ３ｌ系キメラタンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240122983A1 (de) |
| EP (1) | EP3843755A4 (de) |
| JP (1) | JP2022512540A (de) |
| CN (1) | CN112888711A (de) |
| AU (1) | AU2019333175A1 (de) |
| CA (1) | CA3109352A1 (de) |
| IL (1) | IL281088A (de) |
| MX (1) | MX2021002289A (de) |
| WO (1) | WO2020047327A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3990476A1 (de) * | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc-fusionsproteine und verfahren zur verwendung |
| JP2023506501A (ja) * | 2019-12-16 | 2023-02-16 | ワシントン・ユニバーシティ | キメラ抗原受容体樹状細胞（ｃａｒ－ｄｃ）ならびにこれを作製および使用する方法 |
| WO2022089418A1 (zh) * | 2020-10-26 | 2022-05-05 | 信达生物制药(苏州)有限公司 | 重组截短FLT3配体与人抗体Fc的融合蛋白 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| EP1276501B9 (de) * | 2000-04-25 | 2007-01-24 | Immunex Corporation | Behandlung von tumoren mit photodynamischer therapie |
| WO2002066044A2 (en) * | 2000-10-24 | 2002-08-29 | Immunex Corporation | Method for dendritic cells based immunotherapy of tumors using combination therapy |
| CN101198621A (zh) * | 2005-01-25 | 2008-06-11 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
| US20140079704A1 (en) * | 2012-09-11 | 2014-03-20 | The Texas A&M University System | BI-Specific Diabodies For Masking And Targeting Vaccines |
| SG10201913576RA (en) * | 2015-10-01 | 2020-02-27 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| CN109072253B (zh) * | 2015-12-08 | 2021-12-21 | 延世大学校产学协力团 | 包含GM-CSF基因、Flt3L-TRAIL融合基因、抑制TGF-β表达的shRNA和抑制HSP表达的shRNA的抗肿瘤组合物 |
-
2019
- 2019-08-29 AU AU2019333175A patent/AU2019333175A1/en active Pending
- 2019-08-29 EP EP19854980.0A patent/EP3843755A4/de active Pending
- 2019-08-29 CA CA3109352A patent/CA3109352A1/en active Pending
- 2019-08-29 WO PCT/US2019/048922 patent/WO2020047327A2/en unknown
- 2019-08-29 MX MX2021002289A patent/MX2021002289A/es unknown
- 2019-08-29 JP JP2021511583A patent/JP2022512540A/ja active Pending
- 2019-08-29 CN CN201980068131.4A patent/CN112888711A/zh active Pending
-
2021
- 2021-02-24 IL IL281088A patent/IL281088A/en unknown
-
2023
- 2023-12-26 US US18/396,206 patent/US20240122983A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016341529B2 (en) | Methods for culturing cells and kits and apparatus for same | |
| Watts | TNF/TNFR family members in costimulation of T cell responses | |
| CN100490895C (zh) | 结合cd40的apc激活分子 | |
| Wang et al. | Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges | |
| Fallarino et al. | Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo | |
| Nguyen et al. | Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells | |
| JP7078937B2 (ja) | 免疫細胞を操作するための抗原提示足場 | |
| Gollob et al. | CD2 regulates responsiveness of activated T cells to interleukin 12. | |
| Ding et al. | TNF receptor 1 mediates dendritic cell maturation and CD8 T cell response through two distinct mechanisms | |
| CN112673025B (zh) | 一种包含第三信号受体的嵌合抗原受体及其应用 | |
| Tamada et al. | Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules | |
| US7435585B2 (en) | Auto-stimulating cells and methods for making and using the same | |
| US6297052B1 (en) | B cell culture system comprising high density membrane bound CD40 ligand | |
| CN113501884B (zh) | 靶向B7H3的全人源嵌合抗原受体、iNKT细胞及其用途 | |
| WO2012135132A1 (en) | Compositions and methods to immunize against hepatitis c virus | |
| US20240050570A1 (en) | T Cell Modification | |
| JP2023521966A (ja) | 改変ｂ細胞及びその使用方法 | |
| KR20230070256A (ko) | 이중특이성 재조합 단백질 및 이의 용도 | |
| WO2008118369A2 (en) | Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity | |
| CN113621077B (zh) | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 | |
| JPWO2020047327A5 (de) | ||
| WO2018058432A1 (zh) | 一种多基因重组嵌合抗原受体分子及其应用 | |
| Miconnet et al. | A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response | |
| US20040161806A1 (en) | Cells having transferred proteins, and methods of use thereof | |
| Li et al. | 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo |